Featured Research

from universities, journals, and other organizations

Two common drugs may help treat deadly Middle East Respiratory Syndrome

Date:
September 10, 2013
Source:
University of Washington
Summary:
Treatment with two common drugs reduced viral replication and lung damage when given to monkeys infected with the virus that causes Middle East Respiratory Syndrome. The condition is a deadly pneumonia that has killed more than 100 people, primarily in the Middle East. The new findings show that a combination of interferon-alpha 2b and ribavirin, drugs routinely used to treat hepatitis C, may be effective against this emerging disease.

Electron microscope image of MIddle East Respiratory Syndrome virus particles, colorized in yellow.
Credit: NIAID

Treatment with two common drugs reduced viral replication and lung damage when given to monkeys infected with the virus that causes Middle East Respiratory Syndrome. The condition is deadly pneumonia that has killed more than 100 people, primarily in the Middle East.

Middle East Respiratory Syndrome, or MERS, was first reported in Saudi Arabia last year. The infection is caused by a coronavirus, called MERS-CoV, which is closely related to several coronaviruses that infect bats. About half of patients who developed the syndrome have died. Currently, there is no proven effective treatment.

The new findings show that a combination of interferon-alpha 2b and ribavirin, drugs routinely used to treat hepatitis C, may be an effective treatment for MERS-CoV infection, said Dr. Angela L. Rasmussen, a research scientist in the Department of Microbiology at the University of Washington in Seattle and co-author of the study.

"Because these two drugs are readily available, they could be used immediately to treat patients infected with MERS-CoV," Rasmussen said.

The study was conducted by researchers from the U.S. National Institute of Allergy and Infectious Diseases; the Universite Pierre et Marie Curie in Paris, France; the University of Manitoba in Winnipeg, Canada; and the University of Washington in Seattle. The results were published online September 8 by the journal Nature Medicine. Darryl Falzarano, of the National Institute of Allergy and Infectious Diseases's Rocky Mountain Laboratory in Hamilton, Mont., was the paper's lead author.

Instead of directly targeting the virus like most conventional antivirals, these drugs work primarily by moderating the body's immune response to the virus and by promoting repair of damaged lung tissue, said Rasmussen.

Working with the team of scientists in the UW Viromics Lab, led by Dr. Michael Katze, UW professor of microbiology, Rasmussen and her colleagues watched how the lung cells responded to the new treatment by tracking their gene expression profiles.

They did this by studying RNA extracted from the infected monkeys' lungs to track changes in what is called the transcriptome. When a cell needs to use a gene, it copies the gene's DNA-encoded instructions into RNA. That RNA transcript is then read to direct the assembly of a protein. By using a "lab on a chip" technology, called a microarray, it is possible to detect and measure RNA transcripts from all the genes in a population of cells. By analyzing the transcriptome, it is then possible to track how cells or a tissue respond to infection, a drug, or some other stimulus. In this case, it allows researchers to study the host response to MERS-CoV in the context of the entire complex biological system, rather than one gene at a time.

Treatment with interferon-alpha 2b and ribavirin appeared to have several interesting effects. The combination increased the transcription of genes that fight viral infections, for example, and reduced transcription of genes that promote inflammation. Of particular interest to Rasmussen and her colleagues, however, was the finding that treatment increased the transcription of genes that assist in regulating a protein called sonic hedgehog.

The sonic hedgehog protein helps moderate the immune response so that it targets the virus more precisely. This honing in reduces collateral damage from broader, less discriminate attack, and helps stimulate repair and growth of lung tissue.

During infection with many severe respiratory viruses, such as influenza, much of the damage is done, not by the virus, but by the body's uncontrolled immune response to the virus, Rasmussen said.

The findings of this new study suggest that, in the case of MERS-CoV infections, interferon-alpha 3b and ribavirin may work primarily by reducing damaging inflammation of the lung and promoting healing by altering the host response, rather than directly targeting the virus.

If that is the case, other drugs that can similarly modulate the body's reaction to viral infections may also prove to be effective against MERS-CoV and other infectious agents, she said.


Story Source:

The above story is based on materials provided by University of Washington. The original article was written by Michael McCarthy. Note: Materials may be edited for content and length.


Journal Reference:

  1. Darryl Falzarano, Emmie de Wit, Angela L Rasmussen, Friederike Feldmann, Atsushi Okumura, Dana P Scott, Doug Brining, Trenton Bushmaker, Cynthia Martellaro, Laura Baseler, Arndt G Benecke, Michael G Katze, Vincent J Munster, Heinz Feldmann. Treatment with interferon-α2b and ribavirin improves outcome in MERS-CoV–infected rhesus macaques. Nature Medicine, 2013; DOI: 10.1038/nm.3362

Cite This Page:

University of Washington. "Two common drugs may help treat deadly Middle East Respiratory Syndrome." ScienceDaily. ScienceDaily, 10 September 2013. <www.sciencedaily.com/releases/2013/09/130910171448.htm>.
University of Washington. (2013, September 10). Two common drugs may help treat deadly Middle East Respiratory Syndrome. ScienceDaily. Retrieved July 30, 2014 from www.sciencedaily.com/releases/2013/09/130910171448.htm
University of Washington. "Two common drugs may help treat deadly Middle East Respiratory Syndrome." ScienceDaily. www.sciencedaily.com/releases/2013/09/130910171448.htm (accessed July 30, 2014).

Share This




More Health & Medicine News

Wednesday, July 30, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Health Insurers' Profits Slide

Health Insurers' Profits Slide

Reuters - Business Video Online (July 30, 2014) Obamacare-related costs were said to be behind the profit plunge at Wellpoint and Humana, but Wellpoint sees the new exchanges boosting its earnings for the full year. Fred Katayama reports. Video provided by Reuters
Powered by NewsLook.com
Concern Grows Over Worsening Ebola Crisis

Concern Grows Over Worsening Ebola Crisis

AFP (July 30, 2014) Pan-African airline ASKY has suspended all flights to and from the capitals of Liberia and Sierra Leone amid the worsening Ebola health crisis, which has so far caused 672 deaths in Guinea, Liberia and Sierra Leone. Duration: 00:43 Video provided by AFP
Powered by NewsLook.com
At Least 20 Chikungunya Cases in New Jersey

At Least 20 Chikungunya Cases in New Jersey

AP (July 30, 2014) At least 20 New Jersey residents have tested positive for chikungunya, a mosquito-borne virus that has spread through the Caribbean. (July 30) Video provided by AP
Powered by NewsLook.com
Generics Eat Into Pfizer's Sales

Generics Eat Into Pfizer's Sales

Reuters - Business Video Online (July 29, 2014) Pfizer, the world's largest drug maker, cut full-year revenue forecasts because generics could cut into sales of its anti-arthritis drug, Celebrex. Fred Katayama reports. Video provided by Reuters
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:

More Coverage


Middle East Respiratory Syndrome Coronavirus: MERS-CoV Treatment Effective in Monkeys

Sep. 8, 2013 Scientists report that a combination of two licensed antiviral drugs reduces virus replication and improves clinical outcome in a recently developed monkey model of Middle East respiratory syndrome ... read more
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins